Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 32: 194-197, 1986;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abernethy, M. H.
Right arrow Articles by Evans, R. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abernethy, M. H.
Right arrow Articles by Evans, R. T.

Clinical Chemistry, Vol 32, 194-197, Copyright © 1986 by American Association for Clinical Chemistry

Plasma cholinesterase phenotyping with use of visible-region spectrophotometry

MH Abernethy, PM George, JL Herron and RT Evans

A method that overcomes the difficulties of the 240-nm benzoylcholine method for phenotyping plasma cholinesterases has been developed. After a timed reaction, under the same reaction conditions as in the classic procedure, choline is detected at 500 nm by use of choline oxidase coupled with the peroxidase/phenol/aminoantipyrine system. Cholinesterase activity measurements, calibrated by use of choline iodide as standard, are linearly related to results obtained with propionylthiocholine as substrate at 25 degrees C (y = 0.14x + 0.17, n = 30, r = 0.98). Results of differential inhibition with dibucaine and fluoride are virtually identical with those obtained by the ultraviolet method (y = 0.97x + 4.3, r = 0.995, and y = 0.93x - 0.5, r = 0.987, respectively) and give the same classification of homo- and heterozygotes for the usual, atypical, and fluoride-resistant variants. The new method has substantial advantages in that it eliminates the difficulties associated with measuring small changes in high absorbances at a suboptimal wavelength on a steep portion of the absorption curve.


The following articles in journals at HighWire Press have cited this article:


Home page
 Anesth. Analg.Home page
C. Cerf, M. Mesguish, I. Gabriel, S. Amselem, and P. Duvaldestin
Screening Patients with Prolonged Neuromuscular Blockade After Succinylcholine and Mivacurium
Anesth. Analg., February 1, 2002; 94(2): 461 - 466.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by the American Association for Clinical Chemistry.